1
|
Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, Seguin A, Kouatchet A, Delaunay M, Debieuvre D, Duchemann B, Rousseau-Bussac G, Nyunga M, Grimaldi D, Levrat A, Azoulay E, Lemiale V. ICU admission for solid cancer patients treated with immune checkpoint inhibitors. Ann Intensive Care 2023; 13:29. [PMID: 37072645 PMCID: PMC10113402 DOI: 10.1186/s13613-023-01122-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Accepted: 03/24/2023] [Indexed: 04/20/2023] Open
Abstract
BACKGROUND Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to describe irAEs for ICU admissions in solid cancer patients treated with ICIs. METHODS This prospective multicenter study was conducted in France and Belgium. Adult patients with solid tumor and treated with systemic ICIs within the last 6 months, requiring non-programmed ICU admission were included. Patients admitted for microbiologically documented sepsis were excluded. Imputability of irAEs in ICU admissions was described according to the WHO-UMC classification system at ICU admission and at ICU discharge. The use of immunosuppressant treatment was reported. RESULTS 115 patients were eligible. Solid tumor was mainly lung cancer (n = 76, 66%) and melanoma (n = 18, 16%). They were mainly treated with an anti-PD-(L)1 alone (n = 110, 96%). Main ICU admission reasons were acute respiratory failure (n = 66, 57%), colitis (n = 14, 13%), and cardiovascular disease (n = 13, 11%). ICU admission was considered "likely" associated with irAE for 48% (n = 55) of patients. Factors independently associated with irAE were a good ECOG performance status (PS) (ECOG-PS of 0 or 1 vs. ECOG-PS of 2-3, odds ratio [OR] = 6.34, 95% confidence interval [95% CI] 2.13-18.90, and OR = 3.66, 95% CI 1.33-10.03, respectively), and a history of irAE (OR = 3.28, 95% CI 1.19-9.01). Steroids were prescribed for 41/55 (75%) patients with ICU admission "likely" related to irAE. Three patients were subsequently treated with immunosuppressants. CONCLUSION IrAEs accounted for half of ICU admissions in cancer patients receiving ICIs. They could be treated with steroids. Identifying the imputability of irAEs in ICU admissions remains a challenge.
Collapse
Affiliation(s)
- Anne-Claire Toffart
- Department of Pneumology and Physiology, CHU Grenoble Alpes, Grenoble, France.
| | - Anne-Pascale Meert
- Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Florent Wallet
- Department of Resuscitation, Hospices Civils de Lyon, Lyon, France
| | - Aude Gibelin
- Department of Resuscitation, Hôpital Tenon, AP-HP, Paris, France
| | - Olivier Guisset
- Department of Intensive Care and Resuscitation, Hôpital Saint André, CHU Bordeaux, Bordeaux, France
| | | | - Amélie Seguin
- Department of Resuscitation, CHU de Nantes, Nantes, France
| | | | | | | | - Boris Duchemann
- Department of Thoracic Oncology, Hôpital Avicenne, Bobigny, France
| | | | - Martine Nyunga
- Department of Resuscitation, CH de Roubaix, Roubaix, France
| | - David Grimaldi
- Department of Resuscitation, Cliniques Universitaires de Bruxelles - Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| | - Albrice Levrat
- Department of Resuscitation, CH Annecy Genevois, Annecy, France
| | - Elie Azoulay
- Department of Resuscitation, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Virginie Lemiale
- Department of Resuscitation, Hôpital Saint-Louis, AP-HP, Paris, France
| |
Collapse
|
2
|
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot A, Guisier F, Galland L, Do P, Schott R, Dansin E, Arrondeau J, Auliac J, Chouaid C. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1805] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Valery S, Chouaid C, Rousseau-Bussac G, Monnet I, Bilger G, Boré P, Pinsolle J, Descourt R, Geier M, Toffart A, Cony-Makhoul P, Robinet G, Ennahdi F, Zaccaria I, Decroisette C. Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint inhibitors - AVATAX , a retrospective multicentric study: Preliminary data. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz449.035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer 2019; 136:109-114. [PMID: 31491676 DOI: 10.1016/j.lungcan.2019.08.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 07/17/2019] [Accepted: 08/13/2019] [Indexed: 10/26/2022]
Abstract
OBJECTIVES Brigatinib is a next-generation ALK inhibitor initially developed in ALK-positive NSCLC pretreated with crizotinib. MATERIALS AND METHODS This retrospective multicentric study analyzed ALK-positive advanced NSCLC patients pretreated with at least one tyrosine-kinase inhibitor, including crizotinib, and enrolled in the brigatinib French early access program. The primary endpoint was investigator-assessed progression-free survival (PFS). RESULTS 104 patients were included (mean age, 56.6 years; never smokers, 61.5%; adenocarcinoma, 98.1%). Patients had received a median of 3 previous treatment lines, including at least 2 ALK inhibitors (mainly crizotinib then ceritinib). At brigatinib initiation, 59.1% had performance status 0-1, 51.9% had ≥ 3 metastatic sites, 74.5% had central nervous system metastases (CNS) and 8.8% had carcinomatous meningitis. Median duration of brigatinib treatment was 6.7 (95% CI, 0.06-20.7) months. Median PFS was 6.6 (4.8-9.9) months for the entire population. For patients who received 2, 3-4 and >4 lines of treatment before brigatinib, PFS was 4.3 (2.5-8.9), 10.4 (5.9-13.9) and 3.8 (0.8-7.4) months, respectively. In the 91 evaluable patients, disease control rate was 78.2%. From brigatinib start, median overall survival was 17.2 (11.0-not reached) months. Among the 68 patients with progressive disease after brigatinib, CNS was involved in 29.4% of cases. Median OS from the diagnosis of NSCLC was 75.3 (38.2-174.6) months. CONCLUSION These real-world results confirm the efficacy of brigatinib in a cohort of patients heavily pretreated for ALK-positive advanced NSCLC.
Collapse
Affiliation(s)
- Renaud Descourt
- Centre Hospitalier Universitaire, Oncology Department, Brest, France.
| | | | | | - David Planchard
- Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, France
| | - Bertrand Mennecier
- Centre Hospitalier Universitaire de Strasbourg, Chest Department, Strasbourg, France
| | - Marie Wislez
- AP-HP, Hôpitaux Universitaires de l'Est Parisien, Tenon Hospital, Chest Department, Paris, France; AP-HP, Hôpitaux Universitaires Paris Centre, Cochin Hospital, Thoracic Oncology Unit, Department of Pneumology, Paris, France
| | - Alexis Cortot
- Centre Hospitalier Universitaire de Lille, Thoracic Oncology Unit, Lille, France
| | - Florian Guisier
- Centre Hospitalier Universitaire de Rouen, Chest Department, Rouen, France
| | - Loïck Galland
- Georges-François-Leclerc Cancer Center, Medical Oncology Department, Dijon, France
| | - Pascal Dô
- François-Baclesse Cancer Center, Medical Oncology Department, Caen, France
| | - Roland Schott
- Paul-Strauss Cancer Center, Medical Oncology Department, Strasbourg, France
| | - Eric Dansin
- Oscar-Lambret Cancer Center, Medical Oncology Department, Lille, France
| | - Jennifer Arrondeau
- AP-HP, Hôpitaux Universitaires Paris Centre, Cochin Hospital, Thoracic Oncology Unit, Department of Pneumology, Paris, France
| | | | | |
Collapse
|
5
|
Assie J, Monnet I, Rousseau-Bussac G, Jabot L, Vinas F, Mejri I, Gibiot Q, Boudjemaa A, Chouaid C. Longs survivants après immunothérapie pour cancer du poumon non à petites cellules métastatiques : prévalence, caractéristiques cliniques et modalités de prise en charge. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Mejri I, Boudjemaa A, Viñas F, Gibiot Q, Rousseau-Bussac G, Maître B, Housset B, Mangiapan G. Amélioration de la prise en charge par l’évaluation des pratiques : exemple de la mise en place de la sédation vigile dans une unité d’endoscopie bronchique. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
7
|
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Gervais R, Dansin E, Schott R, Arrondeau J, Dujon C, Madelaine J, Jeannin G, Bylicki O, Daniel C, Spaeth D, Auliac J, Chouaïd C. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petites cellules avec translocation ALK en France. Étude BRIGALK. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Abstract
The advent of immune-checkpoint inhibitors during the past decade represents a major advancement in the treatment of non-small cell lung cancer (NSCLC) with personalized treatment. Platinum-based chemotherapy has reached its efficacy threshold, with its use remaining limited by its toxicity. For NSCLC, inhibitors of the PD1 protein and its ligand PDL1 show promising clinical activity and induce durable responses in patients with advanced disease. The US Food and Drug Administration has approved pembrolizumab for treatment-naïve metastatic NSCLC with ≥50% of tumor cells expressing PDL1 and for metastatic NSCLC with ≥1% PDL1 expression after progression following first-line platinum-based doublet chemotherapy. In 2017, it also authorized the first-line combination of pembrolizumab and carboplatin-pemetrexed chemotherapy without selection based on PDL1 expression, but European health authorities are still waiting for the results of a Phase III trial. In this review, the clinical results of published and ongoing studies evaluating pembrolizumab for advanced NSCLC are analyzed and the potential role of PDL1 as a factor predictive of overall responses addressed.
Collapse
Affiliation(s)
- Olivier Bylicki
- Pneumology Department, Hôpital d'Instruction des Armées Percy, Paris,
| | - Nicolas Paleiron
- Respiratory Department, Hôpital d'Instruction des Armées Saint-Anne, Toulon
| | | | | |
Collapse
|
9
|
Thibault De Menonville C, De Torcy M, Gibiot Q, Vinas F, Rousseau-Bussac G, Jabot L, Monnet I, Chouaid C. Patients avec cancer bronchopulmonaire sous immunothérapie : intérêt du Pet Scanner. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Mangiapan G, Boudjemaa A, Viñas F, Gibiot Q, Benhassen I, Rousseau-Bussac G, Lasseur M, Housset B. Différence entre la mesure échographique et l’épaisseur réelle de la paroi thoracique. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Lasseur M, Boudjemaa A, Viñas F, Gibiot Q, Benhassen I, Rousseau-Bussac G, Housset B, Mangiapan G. Évaluation du contrôle de la douleur induite par les actes pleuraux. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Gendarme S, De Torcy M, Gibiot Q, Ben Assem I, Vinas F, Boudjemaa A, Rousseau-Bussac G, Monnet I, Chouaid C. Prise en charge des cancers bronchopulmonaires non métastatiques avec mutations oncogéniques : quelle place pour les traitements ciblés ? Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Caliez J, Monnet I, Pujals A, Rousseau-Bussac G, Jabot L, Boudjemaa A, Leroy K, Chouaid C. Adénocarcinome bronchique avec mutation de l’ EGFR et réarrangement ALK concomitants. Rev Mal Respir 2017; 34:576-580. [DOI: 10.1016/j.rmr.2016.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 07/11/2016] [Indexed: 12/09/2022]
|
14
|
Selvaratnam S, Chouaid C, Thiriat N, Jabot L, Rousseau-Bussac G, Jaskowiec C, Vinas F, Poullain S, Monnet I. Étude prospective d’une cohorte de patients, atteints de cancer bronchique non à petites cellules, traités par une monothérapie de nivolumab en pratique clinique courante. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Gauvain C, Crequit P, Rousseau-Bussac G, Ganoun A, Baud M, Chouaid C. [Adjuvant chemotherapy of non-small cell lung cancer: Tolerance of combined cisplatin-pemetrexed therapy]. Rev Mal Respir 2014; 31:817-21. [PMID: 25433586 DOI: 10.1016/j.rmr.2013.10.646] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2013] [Accepted: 10/22/2013] [Indexed: 11/25/2022]
Abstract
RATIONALE Adjuvant chemotherapy is standard for non-small cell lung cancer (NSCLC) after surgical resection. In this context, the tolerance of the treatment is an essential criterion in the choice of chemotherapy. This exploratory study evaluated, in the situation of adjuvant chemotherapy, the tolerance of combined cisplatin-pemetrexed. The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. RESULTS The analysis included 23 patients (age: 58.7 ± 5 years, men: 56%, average creatinin clearance (Clea): 94 ± 22 mL/min, average haemoglobin: 13.8 ± 1.6g/dL). Over 92 planned courses, 7.6% are postponed (neutropenia), 4.3% were not given (asthenia). We noted 7 episodes of vomiting (4 grade 3), with two hospitalizations in the same patient; 5 episodes of anaemia grade 1-2 not requiring EPO prescription or transfusion and no febrile neutropenia. At the end of the treatment, three patients had a Clea<50 mL/mn and 5 a haemoglobin between 9 and 11 g/dL. CONCLUSION Combined cisplatin-pemetrexed in an adjuvant situation has a satisfactory tolerance.
Collapse
Affiliation(s)
- C Gauvain
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - P Crequit
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - G Rousseau-Bussac
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - A Ganoun
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - M Baud
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - C Chouaid
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France; Service de pneumologie, centre hospitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.
| |
Collapse
|
16
|
Rousseau-Bussac G, Crequit P, Alifano M, Chouaid C. [Management of malignant pericardial effusion in lung cancer]. Rev Mal Respir 2014; 31:746-53. [PMID: 25391509 DOI: 10.1016/j.rmr.2014.02.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2013] [Accepted: 02/06/2014] [Indexed: 01/19/2023]
Abstract
Acute pericarditis associated with lung cancer is a relatively frequent complication but is usually not symptomatic unless it causes tamponade. The clinical presentation is classically with dyspnea, thoracic pain, signs of right cardiac failure then left cardiac failure and syncope but it is often a difficult diagnosis in a patient with multi-symptomatic disease. The diagnosis is based on cardiac echography. Toxicity due to radiotherapy or more rarely an infectious etiology must be considered. Clinically significant effusions must be drained because of the high rate of recurrence after a simple aspiration. Drainage is formally indicated when, at echocardiography, the effusion exceeds 20mm in diastole, in cases of tamponade or in cases of compromised hemodynamic status. The formation of a pericardial window at thoracotomy prevents recurrences. Based on old, retrospective, very heterogeneous case series the prognosis, is generally considered to be poor with a median survival which does not exceed 100 days and a one year survival generally lower than 10%. Prognosis is better where diagnosis occurs at an earlier stage allowing regular follow-up and surgical intervention in a non-emergency setting.
Collapse
Affiliation(s)
| | - P Crequit
- Service de pneumologie, hôpital Saint-Antoine, Paris, France
| | - M Alifano
- Service de chirurgie thoracique, hôpital Cochin, Paris, France
| | - C Chouaid
- Service de pneumologie, hôpital Saint-Antoine, Paris, France; Service de pneumologie et de pathologie professionnelle, CHI de Créteil, 40, avenue de Verdun, 94010 Créteil, France.
| |
Collapse
|
17
|
Lavolé A, Lejeune C, Epaud C, Rosencher L, Ruppert AM, Gounant V, Créquit P, Rousseau-Bussac G, Wislez M, Cadranel J. Délai de prise en charge du cancer du poumon (CP) en hôpital de jour d’un centre expert en oncologie thoracique. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Gauwin C, Crequit P, Rousseau-Bussac G, Ganoun A, Baud M, Chouaid C. Traitement adjuvant des cancers bronchiques non à petites cellules : tolérance de l’association platine–pemetrexed. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Sese L, Didier M, Rousseau-Bussac G, Crequit P, Masanes MJ, Chouaid C. Chimiothérapies en fin de vie chez les patients pris en charge pour cancers pulmonaires : analyse des pratiques. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
20
|
Rousseau-Bussac G, Strano S, Phin-Huynh S, Regnard JF, Alifano M, Chouaid C. Pronostic des péricardites chez les patients pris en charge pour cancer du poumon. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.759] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Rousseau-Bussac G, Margetis D, Lino A, Galbois A, Phin-Huynh S, Maury E, Chouaid C. Pronostic des patients atteints de cancer du poumon pris en charge en réanimation médicale. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Rousseau-Bussac G, Dixmier A, Papanikolaou I, Baud M, Lebeau B, Chouaid C. 191 Évolution des patients transférés en réanimation dans le cadre de la prise en charge d’un cancer bronchopulmonaire. Rev Mal Respir 2007. [DOI: 10.1016/s0761-8425(07)72567-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|